The weight-loss drug Wegovy reduced the risk of serious heart problems by 20% in a large, international study. This breakthrough could change the way doctors treat certain heart patients.
The research is significant because it shows that an obesity medication can not only help shed pounds but can also safely prevent a heart attack, stroke, or a heart-related death in people who already have heart disease (but not diabetes).
These findings could shift the view that the new class of obesity drugs are merely cosmetic treatments. It may also put pressure on health insurers to cover them.
Dr. Michael Lincoff, the study’s lead author and a heart expert at the Cleveland Clinic, commented, “It moves from a kind of therapy that reduces body weight to a therapy that reduces cardiovascular events.”
Wegovy is a high-dose version of the diabetes treatment Ozempic, which has been shown to reduce the risk of serious heart problems in people with diabetes. The new study investigated if the same was true in those who don’t have the disease.
Dr. Francisco Lopez-Jimenez, a heart expert at the Mayo Clinic, noted that while it’s been known for years that losing weight can improve heart health, there hasn’t been a safe and effective obesity medication proven to reduce specific risks. He expects the new findings to change treatment guidelines and “dominate the conversation” for years to come.
“This is the population who needs the medicine the most,” said Lopez-Jimenez, who had no role in the study.
In the U.S., there are about 6.6 million people like those tested in the study, experts said.
The results were published Saturday in the New England Journal of Medicine and presented at a medical conference in Philadelphia. Novo Nordisk, the maker of Wegovy and Ozempic, has asked the U.S. Food and Drug Administration to include the heart benefits on Wegovy’s label, as with Ozempic’s.
The new study, funded by the company, included more than 17,500 people in 41 countries. Participants were age 45 and older, had a body mass index of 27 or higher, and were tracked for more than three years on average. They took typical drugs for their heart conditions but were also randomly assigned to receive weekly injections of Wegovy or a placebo.
The study found that 569, or 6.5%, of those who got the drug versus 701, or 8%, of those who received the placebo had a heart attack, stroke, or died from a heart-related cause. That’s an overall reduction of 20% in the risk of those outcomes, the researchers reported.
The drop appeared to be primarily fueled by the difference in heart attacks, but the number of serious health complications reported was too small to tell whether the individual outcomes were caused by the drug or by chance.
Study volunteers who took Wegovy lost about 9% of their weight, while the placebo group lost less than 1%.
The Wegovy group also saw drops in key markers of heart disease, including inflammation, cholesterol, blood sugars, blood pressure, and waist circumference, noted Dr. Martha Gulati, a heart expert at Cedars-Sinai Medical Center in Los Angeles. Changes in those markers began early in the study, before participants lost much weight.
“It means to me that it’s more than just weight loss, how this drug works,” said Gulati, who had no role in what she called a landmark study.
Still, “it remains unclear” how much of the results were a benefit of losing weight or the drug itself, as noted in an editorial accompanying the study.
Approximately a third of all study volunteers reported serious side effects. About 17% in the Wegovy group and about 8% in the comparison group left the study, mostly because of nausea, vomiting, diarrhea, and other stomach-related problems.
Nearly three-quarters of participants were men and nearly 84% were white. Gulati and others said future research needs to include more women and racial and ethnic minorities.
Wegovy is part of a new class of injectable medications for obesity. On Wednesday, the U.S. Food and Drug Administration approved Eli Lilly’s Zepbound, a version of the diabetes drug Mounjaro, for weight control.
Both carry high price tags – monthly costs are about $1,300 for Wegovy and about $1,000 for Zepbound. Both have also been in short supply for months, with manufacturers promising to boost supplies.
The medications are often not covered by private health insurance or subject to strict preauthorization requirements. Medicare, the government health plan for older Americans, is prohibited from covering drugs for weight loss alone. However, drugmakers and obesity treatment advocates have been pushing for broader coverage, including asking Congress to pass legislation to mandate that Medicare pays for the drugs.
Results from the latest study and others that show the obesity drugs have a direct effect on costly health problems could be a factor in shifting the calculus of coverage, said Dr. Mark McClellan, former chief of the Centers for Medicare and Medicaid Services and the FDA. In 2006, Medicare was allowed to cover weight-loss surgery to treat the complications of severe obesity, if not obesity itself, he noted.
That approach “may end up being relevant here,” he said.
